Treatment of severe psoriasis with anti-CD25 monoclonal antibodies

被引：42

作者：

Mrowietz, U ^{[1
]}

Zhu, KJ ^{[1
]}

Christophers, E ^{[1
]}

机构：

[1] Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany

来源：

ARCHIVES OF DERMATOLOGY | 2000年 / 136卷 / 05期

关键词：

D O I：

10.1001/archderm.136.5.675

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：675 / 676

页数：2

共 5 条

[1] RESPONSE OF PSORIASIS TO A LYMPHOCYTE-SELECTIVE TOXIN (DAB(389)IL-2) SUGGESTS A PRIMARY IMMUNE, BUT NOT KERATINOCYTE, PATHOGENIC BASIS [J].

GOTTLIEB, SL ;

GILLEAUDEAU, P ;

JOHNSON, R ;

ESTES, L ;

WOODWORTH, TG ;

GOTTLIEB, AB ;

KRUEGER, JG .

NATURE MEDICINE, 1995, 1 (05) :442-447

[2] Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].

Nashan, B ;

Moore, R ;

Amlot, P ;

Schmidt, AG ;

Abeywickrama, K ;

Soulillou, JP .

LANCET, 1997, 350 (9086) :1193-1198

[3]

NICHOLAS JF, 1991, LANCET, V338, P321

[4] Basiliximab [J].

Onrust, SV ;

Wiseman, LR .

DRUGS, 1999, 57 (02) :207-213

[5] CHIMERIC CD4 MONOCLONAL-ANTIBODY IN TREATMENT OF GENERALIZED PUSTULAR PSORIASIS [J].

PRINZ, J ;

BRAUNFALCO, O ;

MEURER, M ;

DADDONA, P ;

REITER, C ;

RIEBER, P ;

RIETHMULLER, G .

LANCET, 1991, 338 (8762) :320-321

← 1 →